Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kenporen Generally Satisfied with Improvements of Distribution Business Practices
November 24, 2008
- Nippon Shinyaku: Sales Up 14.1% Due to Licensing of NS-304
November 24, 2008
- REGULATORY NEWS IN BRIEF
November 24, 2008
- Seikagaku: Good Domestic Sales Fail to Make Up for Decreases in Exports
November 24, 2008
- Savings of Up to \18 Tril. Possible by Self Med: NRK Report
November 24, 2008
- MEDICAL DEVICE NEWS IN BRIEF
November 24, 2008
- Zeria: Poor Sales of Healthcare Products Depress Overall Performance
November 24, 2008
- Controversies Continue over On-line Sale of Drugs
November 24, 2008
- Top-Six Wholesalers' Profits Hit by Soft Market Prices
November 24, 2008
- ASKA: Generics Bolster Business
November 24, 2008
- Bayer Confident about Success in the Healthcare Field: Mr Wenning
November 24, 2008
- 99 Generics Included in Nov. NHI Price Listing
November 17, 2008
- Kyowa Kirin to Focus on Both Small Molecules, Antibodies
November 17, 2008
- Merck Serono to Accelerate Domestic Development to Achieve US$500 Mil. Sales
November 17, 2008
- Bikaken, Lilly TB Drug Discovery Initiative to Jointly Develop CPZEN-45 for XDR-TB
November 17, 2008
- Early Treatment of COPD Essential: UPLIFT Study on Spiriva
November 17, 2008
- 46th JSCO Annual Meeting
November 17, 2008
- Delay in NDA Review by FDA Disappoints Industry: Mr Hasegawa
November 17, 2008
- TOPICS／2008 JCA-Mauvernay Award Granted to Profs. H. Ichijo and H. Mano
November 17, 2008
- Astellas: R&D Costs Depress Operating Profits 11%
November 17, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…